New study explores how genetic risk info shapes ovarian cancer decisions
NCT ID NCT06436248
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study interviews 24 women with BRCA1 or BRCA2 mutations to learn how they might use polygenic risk scores and multi-cancer early detection tests when deciding about cancer screening or risk-reducing surgery. The goal is to better understand patient attitudes, not to test a treatment. Results could help doctors support informed decision-making.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRCA MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new PET tracer light up hidden cancers?
- A Two-for-One surgery: could tube removal during Weight-Loss surgery slash ovarian cancer risk?
- Can AI spot ovarian cancer on CT scans before It's too late?
- Can Lab-Grown tumors unlock the secrets of ovarian cancer resistance?
- Can a smart drug home in on Hard-to-Treat cancers?